To view this email as a web page, go here.
DNDi e-newsBest Science for the Most Neglected

- news

Dear Friends, Colleagues, and Partners,

DNDi, today, is pleased to send you its first electronic newsletter to give you an overview of our recent efforts, progresses, and achievements. From now on, an e-news will be sent to you on a bi-monthly basis and will keep you updated on our activities around the world. We hope you find this e-news useful and informative and look forward to providing you with this new service.

Best regards,

Your DNDi team

PS: If you do not wish to receive this newsletter, please click on “unsubscribe” at the bottom of this e-news.

Access to treatments: 6 endemic countries have already accepted NECT (nifurtimox-eflornithine combination therapy) as a treatment against sleeping sickness. NECT has been recently made available by DNDi and its partners. read more»

Clinical research to treat Chagas disease: The Barcelona Centre for International Health Research and the Clinic Foundation for Biomedical Research signed an agreement with DNDi to join forces on clinical research on Chagas disease. read more» 

Access to new compounds:
Pfizer and DNDi are working together to advance international research efforts in the fight against neglected tropical diseases. read more»

Funding for sleeping sickness: DNDi has recently received US$15M from the Bill and Melinda Gates Foundation. The grant will help develop a promising new medicine against sleeping sickness. read more»

Regulatory process in Africa: DNDi and the George Institute for International Health have published a new report with several recommendations on regulatory processes: “Registering New Drugs: The African context”. read more»

R&D competition: DNDi is partnering with Nature and InnoCentive to challenge the scientific community worldwide to obtain potential targets for drugs against sleeping sickness, leishmaniasis, and Chagas disease. read more»


Visceral leishmaniasis: “Combination therapy for visceral leishmaniasis” published in  The Lancet Infectious Diseases, Volume 10, Issue 3, March 2010. read more»

DNDi’s projects: DNDi’s new portfolio map is available in English, Spanish, and Portuguese. read more»


Neue Zürcher Zeitung: „New R&D models for most neglected diseases - Neue Forschungsmodelle für vernachlässigte Krankheiten“ (German). read more»

La Recherche: "We develop innovative medicines for the poorest" - "Nous créons des médicaments innovants pour les plus pauvres" (French). read more»


United States Congressional Malaria & Neglected Tropical Diseases (NTDs) Caucus Briefing, Washington, D.C.:  "Controlling Deadly Neglected Tropical Diseases: Opportunities to expand the US impact": DNDi and Médecins Sans Frontières/Doctors Without Borders (MSF) call for the inclusion of deadly NTDs and funding for new drug R&D  in U.S. policies, such as the Obama Administration’s new Global Health Initiative (GHI) and 2011 budget. Deadly NTDs such as sleeping sickness, visceral leishmaniasis, and Chagas disease were not included in the GHI, nor was R&D for urgently needed new drugs to replace outdated, toxic, expensive and ineffective tools. On February 22nd, Congressmen Payne and Boozman sponsored a Capitol Hill briefing during which experts from DNDi, MSF, and RTI International research institute informed US policymakers on this issue. read more»

DNDi at COHRED/NEPAD meeting, Pretoria: DNDi participated in this meeting to debate on "Strengthening access to medicine and pharmaceutical innovation in Africa”. DNDi and the George Institute for International Health launched a report on "Registering new drugs: The African context". read more»

DNDi Worldwide

Africa: The HAT Platform Newsletter N° 6 is available in English and French. read more»

Latin America: Latin American DNDi’s new website launched with specific information about DNDi’s activities in the region. read more»

Japan: The Japanese pharmaceutical company Eisai and DNDi have started a collaboration to develop a new drug for Chagas disease. read more»